REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$781.49
arrow_downward
-1.48%(-11.77) 1D
Sep 11, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$800.00
High
$800.22
Low
$780.81
Mkt. cap
80.46B
Avg. vol.
728.61K
Volume
0.00
Dividend
0.48%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.32
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
Open
$800.00
High
$800.22
Low
$780.81
Mkt. cap
80.46B
Avg. vol.
728.61K
Volume
0.00
Dividend
0.48%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
19.32
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.20
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
ad-hoc-news.de
·
5 hours ago
Regeneron stock heads into the open after a 1.5 percent drop
The National Law Review
·
18 hours ago
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds
PR Newswire
·
18 hours ago
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
GlobeNewswire
·
1 day ago
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc.
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com